Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-ASPEN: REGN7508 vs acetylsalicylic acid for venous thromboprophylaxis after total knee arthroplasty
2025-520479-25-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of REGN7508 in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence of the composite endpoint of symptomatic venous thromboembolism and VTE-related death. Planned start Apr 2026; status: authorised.
02
Drugs
REGN7508
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2025-520479-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520479-25-00.